Eli Lilly and Company
Eli Lilly Reports Strong Q3 2025 Results with 54% Revenue Growth and Raised Guidance
Summary
Eli Lilly and Company reported a robust third-quarter 2025 financial performance with a 54% increase in revenue to $17.60 billion, driven by strong demand for Mounjaro and Zepbound. Net income surged to $5.58 billion, and earnings per share (EPS) reached $6.21 on a reported basis and $7.02 on a non-GAAP basis. The company also raised its full-year 2025 revenue guidance to a range of $63.0 billion to $63.5 billion and updated its EPS guidance to $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis. Pipeline progress and regulatory approvals further support the company's growth trajectory.
Profitelligence Alerts
Get alerts for LLY
Be first to know when Eli Lilly and Company files with the SEC.
Filing Categories
Advertisement
About Eli Lilly and Company
Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.
Official SEC Documents
Advertisement